Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation ...
Heavy ligands such as polyoxometalates are opening a new frontier in actinide chemistry. Studying materials that are both ...
Curium Pharma has completed its acquisition of Eczacıbaşı-Monrol Nuclear Products Co., enhancing its capacity in nuclear ...
Curium Pharma, a developer, manufacturer, and distributor of nuclear medicine, has acquired Eczacıbaşı-Monrol Nuclear ...
Positions Curium as leading manufacturer of Lu-177 isotopeBrings innovative R&D expertise and pipeline to Curium Enhances Curium's SPECT & PET ...
Monrol complements and adds to Curium's extensive research & development (R&D) capabilities as it continues to expand its ...
Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...